This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

What is the main barrier raised by your patients with type 2 diabetes when you discuss insulin initiation?
{{answer.value}}%

1.

ADA Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45:S125–S143.

2.

Rubino A, et al. Diabet Med 2007; 24:1412-1418.

3.

Hosomura N, et al. Diabet Med 2017; 34:1599–1602.

4.

Guzman SJ. Diabetes Spectr 2020 Feb;33(1):38–43.

5.

Okemah J, et al. Adv Ther. 2018; 35(11): 1735–1745.

6.

Peyrot M, et al. Diabet Med 2012;29:682–689.

7.

Ellis K et al. BMC Fam Pract 2018; 19:70.

8.

Brod M et al. Patient 2014; 7:437–450.